Q3 2022 Results
Company overview
Financial performance
Financial review
2022 priorities
Appendix
Innovation: Clinical trials
Innovation: Pipeline overview
Novartis pipeline in registration
Solid Tumors
Code
Name
VDT482
Tislelizumab
DRB436 Tafinlar® +MekinistⓇ
Immunology
Mechanism
PD1 inhibitor
BRAF inhibitor + MEK
inhibitor
Code
Name
Mechanism
AIN457
IGE025
CosentyxⓇ
XolairⓇ
IL17A inhibitor
IgE inhibitor
1. Approved in US.
Indication(s)
2L ESCC
Non-small cell lung cancer
HGG/LGG, pediatrics
Indication(s)
Hidradenitis suppurativa
Auto-injector
Cardiovascular
Code
LCZ696
Name
Entresto®
References
Abbreviations
1 lead indication
Mechanism
Indication(s)
Angiotensin receptor/neprilysin Congestive heart failure, pediatrics1)
inhibitor
Lead indication
40 Investor Relations | Q3 2022 Results
NOVARTIS | Reimagining MedicineView entire presentation